Suppr超能文献

肿瘤环境下生物重建中的移植物感染:文献系统综述

Graft Infections in Biologic Reconstructions in the Oncologic Setting: A Systematic Review of the Literature.

作者信息

Sambri Andrea, Zunarelli Renato, Morante Lorenzo, Paganelli Chiara, Parisi Stefania Claudia, Bortoli Marta, Montanari Andrea, Fiore Michele, Scollo Cristina, Bruschi Alessandro, De Paolis Massimiliano

机构信息

Orthopedic and Traumatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.

出版信息

J Clin Med. 2024 Aug 8;13(16):4656. doi: 10.3390/jcm13164656.

Abstract

Biologic graft infection (BGI) is one of the main complications in graft reconstructions. However, very little evidence exists regarding the epidemiology of BGI, as most of the data come from sparse reports. Moreover, most of the series did not detail the treatment and outcome of graft infections. The aim of this systematic review of the literature is to provide a comprehensive data collection on BGI after oncologic resections. Three different databases (PubMed, Scopus, and Web of Science) were searched for relevant articles, and further references were obtained by cross-referencing. 139 studies met the inclusion criteria. A total of 9824 grafts were retrieved. Among these, 684 (6.9%) were in the humerus, 365 (3.7%) in the pelvis, 2041 (20.7%) in the femur and 1660 (16.8%) in the tibia. Most grafts were osteoarticular (2481, 26.7%) and intercalary 2112 (22.7%) allografts. In 461 (5.0%), vascularized fibula grafts (VFGs) were used in combination with recycled autografts. Recycled grafts were reported in 1573 (16.9%) of the cases, and allograft-prosthetic composites in 1673 (18.0%). The pelvis and the tibia had the highest incidence of BGI (20.4% and 11.0%, respectively). The most reported first treatment was debridement and implant retention (DAIR) in 187 (42.8%) cases and two-stage revision with graft removal in 152 (34.8%). Very little data are reported on the final outcome specified by site or type of graft. This systematic review of the literature confirms a high incidence of infections in biologic reconstructions after resections of primary bone tumors. Despite DAIR being a viable attempt, in most cases, a two-stage approach with graft removal and reconstruction with endoprosthesis presented the highest chance to overcome infection, guaranteeing a reconstruction. We emphasize the need for future multicentric studies to focus on the management of infections after biological reconstructions in bone sarcomas.

摘要

生物移植物感染(BGI)是移植物重建中的主要并发症之一。然而,关于BGI流行病学的证据非常少,因为大多数数据来自零散的报告。此外,大多数系列研究并未详细说明移植物感染的治疗方法和结果。本系统文献综述的目的是提供肿瘤切除术后BGI的全面数据收集。检索了三个不同的数据库(PubMed、Scopus和Web of Science)以查找相关文章,并通过交叉引用获得了更多参考文献。139项研究符合纳入标准。共检索到9824个移植物。其中,684个(6.9%)位于肱骨,365个(3.7%)位于骨盆,2041个(20.7%)位于股骨,1660个(16.8%)位于胫骨。大多数移植物为骨关节移植物(2481个,26.7%)和节段间同种异体移植物2112个(22.7%)。在461个(5.0%)病例中,血管化腓骨移植物(VFG)与回收的自体移植物联合使用。1573个(16.9%)病例报告使用了回收移植物,1673个(18.0%)病例使用了同种异体移植物-假体复合物。骨盆和胫骨的BGI发病率最高(分别为20.4%和11.0%)。最常报告的首次治疗是清创并保留植入物(DAIR),共187例(42.8%),以及二期翻修并取出移植物,共152例(34.8%)。关于按移植物部位或类型指定的最终结果的报告数据非常少。本系统文献综述证实,原发性骨肿瘤切除术后生物重建中感染的发生率很高。尽管DAIR是一种可行的尝试,但在大多数情况下,采用取出移植物并使用假体进行重建的两阶段方法克服感染的机会最大,同时保证了重建效果。我们强调,未来的多中心研究需要关注骨肉瘤生物重建后感染的管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5a8/11354657/343a06117345/jcm-13-04656-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验